Podiatric assessment in children and adults with epidermolysis bullosa: are foot and ankle patient-reported outcome measures (PROMs) able to measure the severity of podiatric involvement among EB patients? : International Journal of Women's Dermatology

Secondary Logo

Journal Logo

Review Article

Podiatric assessment in children and adults with epidermolysis bullosa: are foot and ankle patient-reported outcome measures (PROMs) able to measure the severity of podiatric involvement among EB patients?

Wong, Joy Lynna; Khan, Mohammed Tariq PhD, BSc (Hons), BSc (PodMed), CSci, MRCPod, FRCPodM, FFPM RCPS (Glasgow), FLSa,b,c,d,e,f,g; Cowan, Timothy L. BSc, MBBS (Hons)a,b,c; Murrell, Dedée F. MA, BMBCh, FAAD, MD, FACD, FRCP(Edin)a,b,c,*

Author Information
International Journal of Women’s Dermatology 9(1):p e046, March 2023. | DOI: 10.1097/JW9.0000000000000046


What is known about this subject in regards to women and their families?

  • Epidermolysis bullosa (EB) disproportionately affects children, with a greater incidence in younger age groups, as seen in a cohort study across 17 EB centers.
  • The majority of those with EB experience podiatric symptoms and blistering of the foot, which negatively affect physical functioning, appearance, and self-esteem, especially in young people and women.
  • To date, no EB-specific podiatric assessment tool has been developed to objectively assess patient-reported outcomes.

What is new from this article as messages for women and their families?

  • Identification of existing validated foot patient-reported outcome measures used in other podiatric-related conditions and how they could be adapted for use in EB assessment across all demographics and age groups.
  • Explore assessment domains relevant to EB patient-reported outcomes including foot function, activity limitations, pain, footwear, and foot health-related quality of life.


This review will discuss the podiatric involvement of epidermolysis bullosa (EB) patients and assess the relevance of validated patient-reported outcome measures (PROMs) to foot problems in patients with EB. The purpose of this study was to explore the suitability of commonly used foot and ankle PROMs and potentially adapt them for use in studies assessing podiatric severity and interventions among EB patients.


A literature review was conducted to identify clinical studies and systematic reviews investigating foot health and podiatric manifestations using validated foot health PROMs across foot and ankle conditions. The most recent articles relating to podiatric assessment were identified across electronic search engines: National Institutes of Health databases (PubMed and Medline), Google Scholar, and the Consensus-based Standards for the Selection of Health Measurement Instrument (COSMIN) database of systematic reviews. Key phrases used to identify such articles include “Foot [Abnormalities, Analysis, Drug Effects, Injuries, Pathology, Surgery],” “foot deformities/foot diseases/foot ulcer,” “Surveys and Questionnaires,” “patient outcome assessment/treatment outcome/quality improvement/quality indicators.”

Overview of EB and literature documenting podiatric severity

Introduction to EB

EB represents a group of rare inherited skin fragility disorders characterized by painful blistering of the skin upon minor mechanical trauma, leading to erosions and non-healing ulcers.3 EB typically presents at birth or early in life with an incidence of approximately 20 per million live births.4 EB disproportionately affects children; most EB patients fall under the 1 to 9 and 10 to 19 age groups, according to a cohort study across 17 EB centers.5

There are 4 main groups of EB (EB Simplex, Junctional EB, Dystrophic EB, Kindler EB), classified according to the level of skin cleavage. They are further classified based on the mode of inheritance and a combination of phenotypic, ultrastructural, immunohistochemical, and molecular findings.6 The distribution and severity of skin blistering are dependent on the subtype of EB—blistering in milder forms is confined to the hands and feet, while severe forms of EB can lead to extensive chronic wounds that cause significant disability.3

Podiatric involvement among EB patients and its significance

Ninety percent of patients with EB have podiatric manifestations, including blistering, hyperkeratosis, nail dystrophy, and structural abnormalities affecting foot positioning.7,8Figure 1A–F illustrates some of the podiatric manifestations found in patients with EB. Foot pain in EB is often neuropathic and sometimes unbearable.9 These podiatric manifestations inadvertently affect physical well-being and activities of daily living. A cohort study reflected a significant percentage of EB patients experiencing walking or standing limitations due to cutaneous pain, with only up to one-third of all children with EB being independent in walking.10 In more severe types of EB, foot deformities such as extension and flexion contractures of the toes, equinus, cavus, and pseudosyndactyly have been observed, resulting in permanent reliance on a wheelchair.11

Fig. 1.:
Podiatric manifestations in epidermolysis bullosa (EB) patients (Courtesy of Professor Dédée F. Murrell and Dr. Mohammed Tariq Khan, Sydney, Australia). (A) Vesicle formation and blistering of the foot. (B) Loss of toe nails (anonychia) in EB simplex. (C) Erosions and scarring of the foot in junctional EB. (D and E) Keratoderma of the foot and nails in EB simplex. (F) Fusion of toes (pseudosyndactyly).

Such podiatric manifestations can exacerbate psychological difficulties and self-esteem. In a study interviewing children with EB, concerns about appearance, isolation, and feelings about being different were raised.12 Studies have shown that restricted choices of therapeutic and functional footwear can lead to feelings of exclusion, self-consciousness, and vulnerability.13 This is especially significant among female patients, where an emotional relationship and sense of personal identity tied to the type of shoe worn may be negatively impacted by podiatric manifestations.14

Despite the impact of podiatric involvement among patients with EB, limited literature has documented its significance. Less priority may be given to addressing foot problems among EB patients when other medical concerns demand more urgent attention.15 Recently, Khan et al. published an evidence-based guideline on foot care in EB and noted the importance of validated foot assessment tools to measure the foot health status of EB patients.7

EB studies assessing podiatric interventions

Among the few studies assessing podiatric interventions used among EB patients, none used a validated foot assessment tool to measure patient outcomes.11,16–18 Instead, subjective methods of observation or numerical pain scales were used to assess the efficacy of the intervention. Their subjective methods of patient outcome assessment undermine the clinical relevance of the intervention introduced. Hence, a validated EB-specific foot PROM would standardize the parameters of measured patient improvement from the intervention.

EB assessment tools

EB patient assessment tools have been developed, and questionnaires such as QOLEB, BEBS, EBDASI, and iscorEB have been validated and are reliable in distinguishing subtypes of EB.19–24 However, these tools often offer comprehensive rather than region-specific assessment approaches. For example, iscorEB evaluates skin, mucosal, and internal organ involvement, laboratory abnormalities, and complications.19 As such, these disease-specific assessment tools may not be applicable to podiatric/region-specific interventions and consequently downplay the severity of foot involvement compared to other regions affected.

Psychometric properties

Minimal clinically important difference (MCID) is defined as the smallest difference in score in the domain of interest which patients perceive as beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient’s management.23

Cronbach α is the measure of internal consistency: how closely related a set of items are as a group. Cronbach α ≥ 0.70 for each unidimensional scale or subscale was sufficient.23

Intraclass correlation coefficient (ICC) is a widely used reliability index in test–retest reliability analyses.24

Assessment of foot and ankle PROMs

Importance of PROMs

PROMs can be categorized as generic health status measures, disease-specific health status measures, and anatomic scales. Most foot-related PROMs developed are anatomic scales which are region-specific to the foot and/or ankle.25 They are used to objectively detect changes in a patient’s foot health status in response to an intervention and assist clinicians’ understanding of the effects of podiatric manifestations on one’s functioning.26,27

Despite the severity of podiatric involvement and its impact on foot health-related quality of life (HRQoL) among patients with EB, no research has been undertaken to determine the suitability of foot PROMs for genetic dermatoses involving the feet.

PROMs used across foot and ankle conditions

A 2017 systematic review identified 50 PROMs available across all foot and ankle conditions, the majority of which were anatomic-type instruments.28 As shown in Table 1, none of the identified PROMs has been consistently used across all foot and ankle conditions. Moreover, some PROMs were favored in their use for specific categories of foot and ankle pathologies based on the content properties of its questions, and multiple PROMs were usually used together to assess podiatric outcomes.

Table 1 - Systematic and literature reviews evaluating patient-reported outcome measures (PROMs) across various foot and ankle conditions
Year Author Study type Condition Purpose of study Top PROMs Type of PROM Comment
2017 Jia et al. 28 Systematic review All foot and ankle conditions (1) Identify currently available PROMs for foot or ankle disease patients
(2) Critically appraise, compare and synthesize the psychometric evidence for the identified PROMs
Across 50 instruments for patients with foot or ankle diseases, the FFI was the most explored instrument and the MOXFQ had the best overall evidence for psychometric properties
2018 Sierevelt et al. 39 Systematic review Orthopedic foot and ankle conditions To identify the most frequently used foot and ankle-specific PROMs in recent orthopedic foot and ankle literature FFI
The 3 most commonly used outcome measures were the FFI, FAOS, FAAM, capturing 50% of the citations of all 21 outcome measures. Evidence for some psychometric properties of the FAOS and FAAM are lacking/limited
2019 Ortega-Avila et al. 56 Systematic review Rheumatoid arthritis To identify self-reported outcome measures specific to the foot and ankle in patients with rheumatoid arthritis and to investigate the methodological quality and psychometric properties of these measures SEFAS
SEFAS has the best overall psychometric properties and methodological quality, and is currently the most appropriate PROM available for patients with rheumatoid arthritis
2018 Lundgren-Nilsson et al. 57 Systematic review Osteoarthritis To describe the available PROMs used in osteoarthritis and their performance quality WOMAC
WOMAC, SF36 and KOOS were the most frequently used PROMs in osteoarthritis published papers from 2000 to 2016
2015 Schrier et al. 58 Literature review Hallux Surgery To identify and rate available PROMs in hallux valgus surgery MOXFQ
The MOXFQ scores best on positively rated qualities, and SEFAS is a less ideal but good alternative. The VAS is the best pain score and the SF36 the best general health assessment tool
2019 Ortega-Avila et al. Systematic review Diabetic foot To identify PROMs that are specific to diabetic foot and evaluate their psychometric properties and methodological quality FHSQ
Among the 11 PROMs identified, the FHSQ provided the best overall psychometric properties, while FAAM is the most commonly used PROM for diabetic foot studies
2012 Hogg et al. 59 Systematic review Diabetic foot To summarize and analyze the literature pertaining to HRQoL PROMs used in the spectrum of diabetes-related foot disease CWIS
Of the generic tools, the SF-36 shows sensitivity to foot disease and has been used most frequently. Of the disease-specific tools, the DFUS and NeuroQoL are the most validated. The CWIS shows promise in assessing HRQOL in active ulceration, but is non-specific for diabetic foot ulcers
2014 Gorecki et al. 60 Systematic review Chronic wounds; pressure ulcer (PU) To identify generic, PU-specific and chronic skin wound-specific PROMs used to assess HRQoL in patients with PUs or other chronic skin wounds and determine their suitability for use in patients with PUs SF-36 Generic Findings demonstrate that each PROM presented some degree of irrelevant content for this population. The most frequently applied measure used in PU HRQoL research, the SF36, is not conceptually comprehensive in its assessment of HRQoL outcomes important in PUs
CWIS, Cardiff Wound Impact Schedule; FAAM, Foot and Ankle Ability Measure; FFI, Foot Function Index; FAOS, Foot and Ankle Outcome Score; HRQOL, health-related quality of life; KOOS, Knee Injury and Osteoarthritis Outcome Score; MOXFQ, Manchester Oxford Foot Questionnaire; SAFE, Salford Rheumatoid Arthritis Foot Evaluation; SEFAS, Self-Reported Foot and Ankle Score; SF-36, 36 Item Short Form Survey (QoL); VAS, Visual Analogue Scale (pain); WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

For orthopedic conditions, anatomic foot PROMs (Foot Health Status Questionnaire [FHSQ], Manchester Oxford Foot Questionnaire [MOXFQ], Foot Function Index [FFI], Foot and Ankle Outcome Score [FAOS], Foot and Ankle Ability Measure [FAAM], Self-Reported Foot and Ankle Score [SEFAS]) have been favored in clinical studies. Osteoarthritis-related clinical studies favor disease-specific tools (Western Ontario and McMaster Universities Osteoarthritis Index, Knee Injury and Osteoarthritis Outcome Score, FAOS). For diabetic foot, a mixture of anatomic (FHSQ, FAAM), disease-specific (DFUS), and generic (Cardiff Wound Impact Schedule [CWIS], SF36) PROMs has been favored in clinical studies. In clinical studies related to chronic wounds, a generic PROM (SF36) was used to comprehensively assess HRQoL outcomes.

The wide spectrum of podiatric involvement among patients with EB makes it difficult to choose a single suitable PROM to measure the effect of podiatric interventions. The questionnaire’s purpose and content, practical considerations (administration, interpretability, etc.), and evidence for psychometric properties (Fig. 2) using the COSMIN should be evaluated to determine suitability.1

Fig. 2.:
Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) taxonomy of psychometric properties to validate a patient-reported outcome measures (PROM).1

Table 2 describes the domains and properties of PROMs (FHSQ, FFI, MOXFQ, FAAM, FAOS, SEFAS, DFUS, CWIS) relevant to assessing EB-specific foot manifestations. Of the tools evaluated in Table 2, 3 region-specific instruments (FHSQ, FFI, MOXFQ) were deemed potentially appropriate for EB podiatric studies based on their purpose, intended population, and content of the questions. Evidence for the psychometric properties of the FHSQ, FFI, and MOXFQ is compiled in Table 3.

Table 2 - Description of self-administered patient-reported outcome measures (PROMs)
PROM Author Year No. of items and domains Purpose Domains Feasibility Response options Scoring interpretation
Foot Health Status Questionnaire (FHSQ) Benett et al. 29 1998 13 items; 4 domains Measure foot HRQoL • Pain
• Function
• Footwear
• General foot health
3–5 min 5-point Likert scale
1 = None
5 = Severe/always
Individual item scores are re-coded, tabulated, and transformed to a scale ranging from 0 to 100 for each of the 4 domains
Higher scores represent better foot health
Foot Function Index (FFI) Budiman-Mak et al. 37 1991 23 items; 3 domains Measure impact of foot pathology on function • Pain
• Disability
• Activity limitations
3–5 min VAS
1 = No pain/no difficulty
10 = Worst pain imaginable
The VAS for each item is measured to obtain a score out of 10. The item scores are totaled and then divided by the maximum total possible for all of the subscale items which the patient indicated were applicable
Higher scores represent worse foot health
Manchester Oxford Foot Questionnaire (MOXFQ) Dawson et al. 47 2006 16 items; 3 domains PROM for surgery of the foot and ankle • Activity limitation (walking/standing)
• Pain
• Social interaction
3–5 min 5-point Likert scale
0 = None
4 = Severe/all of the time
Scores for each domain are calculated by summing the responses to each item within a given domain. Raw scores can be converted to a 0–100 metric
Higher scores represent worse foot health
Foot Ankle Outcome Score (FAOS) Roos et al. 55 2001 42 items; 5 domains Adapted from the KOOS—to evaluate symptoms and functional limitations related to the foot and ankle • Pain
• Other Symptoms (Stiffness Swelling, and Range of Motion)
• Activities of Daily Living
• Sport and Recreational Activities
• Foot and Ankle-Related Quality of Life
5–10 min 5-point Likert scale
0 = None/never
4 = Extreme/always
Each of the 5 subscale scores is calculated as the sum of the items included. A normalized score ranging from 1 to 100 is calculated for each subscale
Higher scores represent worse foot health
Foot and Ankle Ability Measure (FAAM) Martin et al. 61 2005 29 items; 2 domains Assess physical performance among individuals with a range of leg, foot, and ankle musculoskeletal disorders • Activities of Daily Living
• Sports
5–0 min 5-point Likert scale
0 = Unable to do
4 = No difficulty
Each item on the subscale is scored from 0 to 4. N/A responses are not counted. The score on each of the items are added together and the total score is divided by the highest potential score, which is then transformed into a percentage. Subscale scores range from 0 to 100
Higher scores represent better foot health
HRQOL, health-related quality of life; KOOS, Knee Injury and Osteoarthritis Outcome Score; VAS, Visual Analogue Scale (pain).

Table 3:
Evidence of psychometric properties for FHSQ, FFI, MOXFQ

Foot Health Status Questionnaire

The FHSQ (Supplementary Material A, https://links.lww.com/IJWD/A10) is a region-specific instrument developed in 1998 by Bennett et al. intended for the assessment of patients undergoing surgical treatment for common foot conditions. The FHSQ is a 13-item questionnaire with 4 domains: foot pain, foot function, footwear, and general foot health. Its purpose is to measure foot HRQoL.29


The FHSQ is a short questionnaire that is easily administered and assesses domains relevant to EB podiatric patients. It has been used extensively across a variety of foot and ankle conditions, and has established reasonable psychometric properties. In a developmental study involving 101 participants with skin, nail, and musculoskeletal conditions of the foot, a high degree of internal consistency (Cronbach α = 0.85–0.88), test-retest reliability (intraclass correlation coefficient range = 0.74–0.92), and validity (content, construct, and criterion) were determined.29 In a 2019 systematic review identifying 11 PROMs specific for diabetic foot, the FHSQ provided the best overall psychometric properties, illustrating its usefulness in nonorthopedic-related foot and ankle conditions.30

In studies assessing customized foot orthoses in patients with foot pain and plantar fasciitis, responsiveness across all 4 subscales was observed, and MCID was determined.31,32 This suggests favorable use of the FHSQ in measuring patient outcomes among patients with EB receiving conservative podiatric interventions.


The quality of studies evaluating the psychometric properties of the FHSQ was questioned, which noted inconsistencies in the FHSQ development process and potential limitations in its use.28,33 A practical disadvantage would be the tediousness of score interpretation using a designated program which requires respondents to answer all questions or risk having all their data discarded.33 Some items within the subscales overlapped, creating redundancy, for example, “How would you rate your overall foot health? and “In general, what condition would you say your feet are in?.”33 Additionally, the FHSQ may be unsuitable for children, where 50% of the items may be incomprehensible by respondents aged below 11.34 This increases the respondent burden because a significant proportion of patients with EB are children.

The results of a trial evaluating foot orthoses in plantar fasciitis suggest that the FHSQ may be more responsive to foot conditions without marked disability.35 Additionally, in a prospective cohort study of 115 adults with musculoskeletal foot pain, people with multimorbidity scored worse in each domain of the FHSQ both before and after podiatric intervention than those without.36 Both studies suggest that individuals with multimorbidity and marked disability, such as more severe EB forms, are less likely to perceive modest improvements in foot health.

Foot function index

The original FFI (Supplementary Material B, https://links.lww.com/IJWD/A11) is the most explored region-specific instrument across all foot and ankle conditions, developed by Budiman-Mak et al. in 1991.28 It consists of 23 items across 3 domains: pain, disability, and activity limitations, with the aim of quantifying the impact of foot pathology.37 Since its development, the FFI has been revised and modified, but its revised versions have not been extensively utilized and validated.


One of the main advantages of the FFI is its extensive usage across various foot and ankle pathologies, including congenital, acute and chronic diseases, injuries, and surgical corrections.38 The FFI has also been used in studies involving children, adults, and elderly populations.38 FFI usage, therefore, appeals to clinical studies involving the EB population, where a wide age range exists.

The FFI was developed with good reliability and validity. In the developmental study assessing 87 subjects with rheumatoid arthritis, the FFI demonstrated high internal consistency (Cronbach α = 0.73–0.96), reliability (intraclass correlation coefficient = 0.70–0.87 during 1 week), and construct validity.37 Responsiveness and MCID values were also demonstrated in studies measuring the outcomes of patients with plantar fasciitis.31,35


The methodological quality of studies involving the FFI is insufficient to determine the quality of its psychometric properties. Poor evidence of the psychometric properties of the FFI has been demonstrated by 2 systematic reviews evaluating foot- and ankle-specific PROMs.28,39

The content of the original FFI was considered unsuitable for many patient populations across clinical studies owing to the floor effects of items from the domain of “activity limitations.” Questions regarding the “use of assistive devices indoors/outdoors,” and “stay in bed/indoors most of the day because of foot problems,” were selected as non-applicable by many patients across several studies, particularly those without marked disability.40–46 As such, the FFI appears to be more suitable for low-functioning patients and should be modified according to the study population characteristics.35,39

A practical limitation is the time-consuming efforts of administration, coding, and data entry of the visual analogue scale (pain) score. However, this could be circumvented by using a Likert 5-point scale instead, such as the validated Dutch FFI-5 point version.40

Despite the limitations of the FFI, studies that have modified the FFI (by removing non-applicable questions) and its scoring properties (conversion to a Likert point scale) have shown that it remains a reasonable instrument. Similarly, the FFI can be modified according to the EB population studied.

Manchester Oxford Foot Questionnaire

MOXFQ (Supplementary Material C, https://links.lww.com/IJWD/A12) is a PROM for surgery of the foot and ankle and was developed in 2006 using the MFPDQ as a template.47 This 16-item questionnaire covers 3 domains: functional limitation (walking/standing), pain, and social interaction. It uses a 5-point Likert scale for scoring, and a summary index score is calculated.


One of the key strengths of the MOXFQ is its extensive psychometric evaluation as a foot and ankle surgery PROM, which has provided the best evidence for its psychometric properties across 50 instruments identified for foot and ankle pathology.28 It is well validated in its use across a variety of foot and ankle surgical studies, according to a study which confirmed its suitability among patients undergoing foot and ankle surgery at UK hospitals, with responses showing no floor/ceiling effects.48

In addition to the responsiveness detected in the original validation sample of hallux valgus patients,47 it also appeared to be sensitive to changes 6 months after elective foot surgery.49 The MCID estimates for each subscale have also been determined in various studies.50,51 The MOXFQ is a succinct questionnaire that is easy to interpret and complete and has a high item response rate.34,52


The use of the MOXFQ in nonsurgical studies has been limited and has not been thoroughly examined. Items are more specific to measuring surgical outcomes, which may not be applicable to the majority of EB patients with milder subtypes, thereby creating a floor effect. Moreover, assessment of footwear difficulties is limited to only 1 item enquiring about self-consciousness regarding the type of shoes worn, which may not reflect broader footwear issues faced by patients.53 Additionally, the MOXFQ is not as responsive to change for conservative podiatric interventions such as foot orthoses, as seen in a study comparing the MOXFQ against the FHSQ.54

Other PROMs

Similar to MOXFQ, FAOS and FAAM are region-specific PROMs used in podiatric surgical studies. Additionally, evidence for some psychometric properties (measurement error, content, and structural validity) of the FAOS and FAAM was lacking according to a systematic review.39 The extensive list of items of the FAOS and FAAM mainly focuses on the functional limitations of the foot/ankle (Supplementary Materials D and E, https://links.lww.com/IJWD/A13). Questions of the FAOS placed greater emphasis on joint mobility and symptoms specific to osteoarthritis, which may not be as relevant to milder subtypes of EB.55 However, certain items from the FAOS and FAAM which were not covered by the FHSQ, FFI, and MOXFQ should be considered for their relevance. This includes questions pertaining to foot/ankle joint symptoms, sports and recreational activities, and foot HRQoL.

The domains assessed (social activities, emotions, etc.) in the DFUS and CWIS largely overlapped with those from the validated QOLEB tool; hence, they were not considered for further analysis. Similarly, SEFAS was excluded from consideration, as it only consisted of 12 items covered by the FHSQ, FFI, MOXFQ, FAOS, and FAAM.


To date, no study has formally assessed the effectiveness of podiatric interventions in patients with EB by using a validated foot and ankle PROM. Although validated EB-specific instruments are available, they are not region-specific. The FHSQ, FFI, and MOXFQ were deemed potentially suitable for EB podiatric assessment—they were easy to administer, demonstrated good psychometric properties, and assessed domains relevant to EB patients. Each PROM has its strengths and limitations in use. The FHSQ covered a good range of domains, including footwear, but may not be suitable for assessing EB patients with marked disability and comorbidities. The FFI is the most extensively used tool across various foot and ankle conditions, but some items are not applicable to those without significant disability or assistive devices. The MOXFQ demonstrated the best psychometric properties but has not been widely used in nonsurgical studies; therefore, it is limited in its use among EB patients with milder subtypes (the majority). FAAM and FAOS should also be considered for their wide range of questions, some of which are applicable to EB patients. Such insights into the suitability of foot and ankle PROMs for measuring podiatric severity among EB patients can be used to develop an appropriate EB-specific podiatric PROM, which will set objective parameters for measuring podiatric outcomes and enable clinicians to improve podiatric management among EB patients.

Conflicts of interest




Study approval


Author contributions

JW, TK, and DM contributed to research design, performance of research, data analysis, and writing of the paper. TC contributed to performance of research and writing of the paper.


We wish to thank the following developers of identified foot health questionnaires: Dr Paul Bennett (FHSQ), Dr Elly Budiman-Mak (FFI), Dr Jill Dawson (MOXFQ), Professor Martin Robroy (FAAM), Professor Ewa M. Roos (FAOS). We also wish to thank the clinicians and staff at the EB/bullous clinics of St. George Hospital, Sydney, and Royal Melbourne Hospital. Finally, we would like to thank UNSW librarian, Ressie Davis, for her expert advice on the development of the literature review search strategy.


1. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010;63:737–45.
2. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 2016;15:155–63.
3. Dermatologists ACo. A-Z OF SKIN: Epidermolysis bullosa. Available from: https://www.dermcoll.edu.au/atoz/epidermolysis-bullosa/. 2017. Accessed 2020.
4. Fine J-D. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry. JAMA Dermatol 2016;152:1231–8.
5. Feinstein JA, Jambal P, Peoples K, et al. Assessment of the timing of milestone clinical events in patients with epidermolysis bullosa from North America. JAMA Dermatol 2019;155:196–203.
6. Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 2020;183:614–27.
7. Khan MT, O’Sullivan M, Faitli B, et al. Foot care in epidermolysis bullosa: evidence-based guideline. Br J Dermatol 2020;182:593–604.
8. Khan MT. Podiatric management in epidermolysis bullosa. Dermatol Clin 2010;28:325–33, x.
9. Schrader NHB, Yuen WY, Jonkman MF. Pain quality assessment scale for epidermolysis bullosa. Acta Derm Venereol 2018;98:346–9.
10. Fine J-D, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol 2004;29:122–7.
11. Sternick MB, Formentini PKI, de Souza GMC, Teixeira EC, de Almeida Filho IA, da Costa SM. Treatment of feet deformities in epidermolysis bullosa. Int Orthop 2016;40:1361–5.
12. van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis CG, Jonkman MF. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol 2008;88:143–50.
13. Naidoo S, Anderson S, Mills J, et al. “I could cry, the amount of shoes I can’t get into”: A qualitative exploration of the factors that influence retail footwear selection in women with rheumatoid arthritis. J Foot Ankle Res 2011;4:21.
14. Seferin M, van der Linden J. Protection or pleasure: female footwear. Work 2012;41:290–4.
15. Moss C. Podiatrists gaining a foothold. Br J Dermatol 2020;182:527–8.
16. Barlow A, Parry E. Role of foot orthoses in the management of epidermolysis bullosa simplex. Foot 1999;9:60–4.
17. Kirsner RS, Cassidy S, Marsh C, Vivas A, Kelly RJ. Use of a keratin-based wound dressing in the management of wounds in a patient with recessive dystrophic epidermolysis bullosa. Adv Skin Wound Care 2012;25:400–3.
18. Swartling C, Karlqvist M, Hymnelius K, Weis J, Vahlquist A. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol 2010;163:1072–6.
19. Bruckner AL, Fairclough DL, Feinstein JA, et al. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB). Br J Dermatol 2018;178:1128–34.
20. Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol 2009;161:1323–30.
21. Jain SV, Harris AG, Su JC, et al. The epidermolysis bullosa disease activity and scarring index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. J Eur Acad Dermatol Venereol 2017;31:692–8.
22. Loh CCH, Kim J, Su JC, et al. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol 2014;70:89–97.e1.
23. Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa Severity score: development and validation. Br J Dermatol 2009;160:1057–65.
24. Yuen WY, Frew JW, Veerman K, van den Heuvel ER, Murrell DF, Jonkman MF. Health-related quality of life in epidermolysis bullosa: validation of the Dutch QOLEB questionnaire and assessment in the Dutch population. Acta Derm Venereol 2014;94:442–7.
25. Baumhauer JF, McIntosh S, Rechtine G. Age and sex differences between patient and physician-derived outcome measures in the foot and ankle. J Bone Joint Surg Am 2013;95:209–14.
26. Haywood KL. Patient-reported outcome I: measuring what matters in musculoskeletal care. Musculoskeletal Care 2006;4:187–203.
27. Sloan JA, Dueck A, Qin R, et al. Quality of life: the assessment, analysis, and interpretation of patient-reported outcomes by FAYERS, P. M. and MACHIN, D. Biometrics 2008;64:996.
28. Jia Y, Huang H, Gagnier JJ. A systematic review of measurement properties of patient-reported outcome measures for use in patients with foot or ankle diseases. Qual Life Res 2017;26:1969–2010.
29. Bennett PJ, Patterson C, Wearing S, Baglioni T. Development and validation of a questionnaire designed to measure foot-health status. J Am Podiatr Med Assoc 1998;88:419–28.
30. Ortega-Avila AB, Cervera-Garvi P, Ramos-Petersen L, Chicharro-Luna E, Gijon-Nogueron G. Patient-reported outcome measures for patients with diabetes mellitus associated with foot and ankle pathologies: a systematic review. J Clin Med 2019;8:146.
31. Landorf KB, Radford JA. Minimal important difference: values for the foot health status questionnaire, foot function index and visual analogue scale. Foot 2008;18:15–19.
32. Landorf KB, Radford JA, Hudson S. Minimal Important Difference (MID) of two commonly used outcome measures for foot problems. J Foot Ankle Res 2010;3:7.
33. Trevethan R. Evaluation of two self-referent foot health instruments. Foot 2010;20:101–8.
34. Alvey J, Palmer S, Otter S. A comparison of the readability of two patient-reported outcome measures used to evaluate foot surgery. J Foot Ankle Surg 2012;51:412–4.
35. Landorf KB, Keenan A-M. An evaluation of two foot-specific, health-related quality-of-life measuring instruments. Foot Ankle Int 2002;23:538–46.
36. Hendry GJ, Fenocchi L, Mason H, Steultjens M. The impact of multimorbidity on foot health outcomes in podiatry patients with musculoskeletal foot pain: a prospective observational study. J Foot Ankle Res 2019;12:36.
37. Budiman-Mak E, Conrad KJ, Roach KE. The foot function index: a measure of foot pain and disability. J Clin Epidemiol 1991;44:561–70.
38. Budiman-Mak E, Conrad KJ, Mazza J, Stuck RM. A review of the foot function index and the foot function index – revised. J Foot Ankle Res 2013;6:5.
39. Sierevelt IN, Zwiers R, Schats W, et al. Measurement properties of the most commonly used Foot- and Ankle-Specific Questionnaires: the FFI, FAOS and FAAM. A systematic review. Knee Surg Sports Traumatol Arthrosc 2018;26:2059–73.
40. Kuyvenhoven MM, Gorter KJ, Zuithoff P, Budiman-Mak E, Conrad KJ, Post MW. The foot function index with verbal rating scales (FFI-5pt): a clinimetric evaluation and comparison with the original FFI. J Rheumatol 2002;29:1023–8.
41. Naal FD, Impellizzeri FM, Huber M, Rippstein PF. Cross-cultural adaptation and validation of the Foot Function Index for use in German-speaking patients with foot complaints. Foot Ankle Int 2008;29:1222–8.
42. Saag KG, Saltzman CL, Brown CK, Budiman-Mak E. The foot function index for measuring rheumatoid arthritis pain: evaluating side-to-side reliability. Foot Ankle Int 1996;17:506–10.
43. Martinelli N, Scotto GM, Sartorelli E, Bonifacini C, Bianchi A, Malerba F. Reliability, validity and responsiveness of the Italian version of the Foot Function Index in patients with foot and ankle diseases. Qual Life Res 2014;23:277–84.
44. Venditto T, Tognolo L, Rizzo RS, et al. 17-Italian Foot Function Index with numerical rating scale: development, reliability, and validity of a modified version of the original Foot Function Index. Foot 2015;25:12–18.
45. Wu S-H, Liang H-W, Hou W-H. Reliability and validity of the Taiwan Chinese version of the foot function index. J Formos Med Assoc 2008;107:111–22.
46. Huh JW, Eun IS, Ko YC, et al. Reliability and validity of the Korean version of the foot function index. J Foot Ankle Surg 2016;55:759–61.
47. Dawson J, Coffey J, Doll H, et al. A patient-based questionnaire to assess outcomes of foot surgery: validation in the context of surgery for hallux valgus. Qual Life Res 2006;15:1211–22.
48. Dawson J, Boller I, Doll H, et al. The MOXFQ patient-reported questionnaire: assessment of data quality, reliability and validity in relation to foot and ankle surgery. Foot 2011;21:92–102.
49. Maher AJ, Kilmartin TE. An analysis of Euroqol EQ-5D and Manchester Oxford Foot Questionnaire scores six months following podiatric surgery. J Foot Ankle Res 2012;5:17.
50. Dawson J, Boller I, Doll H, et al. Minimally important change was estimated for the Manchester-Oxford Foot Questionnaire after foot/ankle surgery. J Clin Epidemiol 2014;67:697–705.
51. Dawson J, Doll H, Coffey J, Jenkinson C; Oxford and Birmingham Foot and Ankle Clinical Research Group. Responsiveness and minimally important change for the Manchester-Oxford foot questionnaire (MOXFQ) compared with AOFAS and SF-36 assessments following surgery for hallux valgus. Osteoarthritis Cartilage 2007;15:918–31.
52. Venkatesan M, Aziz S, Mahadevan D, Korim T, Dias J, Bhatia M. Evaluation of validity, reliability, and feasibility of 3 patient-reported foot and ankle outcome measures. J Foot Ankle Surg 2020;59:507–12.
53. Whittaker GA, Munteanu SE, Roddy E, Menz HB. Measures of foot pain, foot function, and general foot health. Arthritis Care Res 2020;72:294–320.
54. Menz HB, Auhl M, Ristevski S, Frescos N, Munteanu SE. Comparison of the responsiveness of the foot health status questionnaire and the Manchester foot pain and disability index in older people. Health Qual Life Outcomes 2014;12:158.
55. Roos EM, Brandsson S, Karlsson J. Validation of the foot and ankle outcome score for ankle ligament reconstruction. Foot Ankle Int 2001;22:788–94.
56. Ortega-Avila AB, Ramos-Petersen L, Cervera-Garvi P, Nester CJ, Morales-Asencio JM, Gijon-Nogueron G. Systematic review of the psychometric properties of patient-reported outcome measures for rheumatoid arthritis in the foot and ankle. Clin Rehabil 2019;33:1788–99.
57. Lundgren-Nilsson A, Dencker A, Palstam A, et al. Patient-reported outcome measures in osteoarthritis: a systematic search and review of their use and psychometric properties. RMD Open 2018;4:e000715.
58. Schrier JCM, Palmen LN, Verheyen CCPM, Jansen J, Koëter S. Patient-reported outcome measures in hallux valgus surgery. A review of literature. Foot Ankle Surg 2015;21:11–15.
59. Hogg FRA, Peach G, Price P, Thompson MM, Hinchliffe RJ. Measures of health-related quality of life in diabetes-related foot disease: a systematic review. Diabetologia 2012;55:552–65.
60. Gorecki C, Nixon J, Lamping DL, Alavi Y, Brown JM. Patient-reported outcome measures for chronic wounds with particular reference to pressure ulcer research: a systematic review. Int J Nurs Stud 2014;51:157–65.
61. Martin RL, Irrgang JJ, Burdett RG, Conti SF, Swearingen JMV. Evidence of validity for the foot and ankle ability measure (FAAM). Foot Ankle Int 2005;26:968–83.
62. Cuesta-Vargas A, Bennett P, Jimenez-Cebrian AM, Labajos-Manzanares MT. The psychometric properties of the Spanish version of the Foot Health Status Questionnaire. Qual Life Res 2013;22:1739–43.
63. Agel J, Beskin JL, Brage M, et al. Reliability of the foot function index: a report of the AOFAS outcomes committee. Foot Ankle Int 2005;26:962–7.
64. Paez-Moguer J, Budiman-Mak E, Cuesta-Vargas AI. Cross-cultural adaptation and validation of the Foot Function Index to Spanish. Foot Ankle Surg 2014;20:34–9.
65. Morley D, Jenkinson C, Doll H, et al. The Manchester-Oxford Foot Questionnaire (MOXFQ): development and validation of a summary index score. Bone Joint Res 2013;2:66–9.
66. Garcés JBG, Winson I, Goldhahn S, et al. Reliability, validity and responsiveness of the Spanish Manchester-Oxford Foot Questionnaire (MOXFQ) in patients with foot or ankle surgery. Foot Ankle Surg 2016;22:59–70.
67. Mousavian A, Ebrahimzadeh MH, Birjandinejad A, Omidi-Kashani F, Kachooei AR. Translation and cultural adaptation of the Manchester-Oxford Foot Questionnaire (MOXFQ) into Persian language. Foot 2015;25:224–7.

blistering skin; epidermolysis bullosa; foot care; patient-reported outcome measure; podiatry; rare disease

Supplemental Digital Content

Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of Women’s Dermatologic Society.